Background: It remains unclear whether left atrial low-voltage area (LALVA) affects atrial tachyarrhythmia recurrence after laser balloon pulmonary vein isolation (PVI) for atrial fibrillation (AF). We prospectively evaluated the outcome of laser balloon PVI in patients with and without LALVA (≤ 0.5 mV) together with surface/intracardiac electrophysiological criteria. 
INTRODUCTION
In patients with drug-refractory symptomatic atrial fibrillation (AF), catheter ablation is the therapy of choice. 1 Pulmonary vein isolation (PVI) leads to acceptable success rates in patients with paroxysmal/persistent AF. [2] [3] [4] The left atrial structural abnormalities identified by late gadolinium enhancement magnetic resonance imaging or bipolar voltage mapping (i.e., left atrial low-voltage area, LALVA) were identified as predictors for atrial tachyarrhythmia recurrence after irrigated radiofrequency current PVI and are currently evaluated as new ablation targets. [5] [6] [7] [8] [9] On the other hand, laser balloon (HeartLight, CardioFocus, Marlborough, MA, USA) has proven efficacy similar to irrigated radiofrequency current PVI. 10, 11 Theoretically, although the difference in durability of PVI between laser balloon (i.e., balloon-based) ablation and radiofrequency current ablation remains unclear, LALVA seems to be a predictor of the atrial tachyarrhythmia recurrence even in laser balloon ablation. However, to our knowledge, this prediction has not been proven in actual clinical research so far. In addition, late gadolinium enhancement magnetic resonance imaging or three-dimensional mapping system is not standard of care during balloon-based PVI. Therefore, the presence of LALVA and the impact on outcome are completely unknown. Hence, we evaluated (1) the results of laser balloon-guided pure PVI regardless of concomitant atrial substrate, (2) the prevalence of LALVA in an unselected AF population, (3) the impact of LALVA on the atrial tachyarrhythmia recurrence rate, and (4) electrocardiographic parameters to predict LALVA without three-dimensional mapping system (total p-wave duration in lead II [PWD] and time interval from the beginning of p-wave to the local activation in left atrial appendage [TTLAA]).
METHODS

Study design
This study is a single-center prospective observational study. Between November 2015 and April 2017, a total of 100 consecutive patients with symptomatic AF (paroxysmal/persistent AF: 68/32 patients) underwent laser balloon PVI. The inclusion criteria were as follows:
(1) drug-refractory nonvalvular paroxysmal AF or persistent AF with a duration of 1 year or less, (2) patients aged 18-80 years, (3) left atrial diameter ≤50 mm, and (4) left ventricular ejection fraction >45%.
The exclusion criteria were as follows: (1) contraindication for PVI, (2) previous PVI attempts, (3) contraindication to oral anticoagulants, (4) presence of intracardiac thrombus, (5) severe mitral valve regurgitation, and (6) moderate mitral valve stenosis.
Left atrial voltage mapping was performed in sinus rhythm before PVI using a 10-pole multielectrode circular mapping catheter (Lasso NAV eco, 15 mm, 1-mm electrodes with 4.5-mm spacing, Biosense Webster, Diamond Bar, CA, USA) with a high-density mapping module (CONFIDENSE TM , CARTO3, Biosense Webster). LALVA was defined as ≤ 0.5 mV during sinus rhythm, as previously described. 7, 8 PWD and TTLAA were measured during the voltage mapping. Patients were subdivided into two groups according to the presence of LALVA: patients with LALVA (group A) and those without LALVA (group B).
The primary endpoint was defined as freedom from documented atrial tachyarrhythmia lasting >30 seconds without antiarrhythmic drugs between 90 and 365 days after the index procedure. The size of LALVA was evaluated by the relative extent of LALVA (rLALVA) in comparison to the entire left atrial surface area (rLALVA = extent of LALVA/left atrial surface area × 100 [%]). The entire left atrial surface area was measured excluding pulmonary veins as the previous report. 9 We compared the primary endpoint (1) between the two groups, as well as (2) between group B and several subgroups with various extents of LVA (minimal rLALVA [<10%] and moderate or more rLALVA [≥ 10%]), and (3) between patients classified based on PWD/TTLAA. The local ethical committee approved this study (local ethics committee number: FF 117/2015). All patients provided written informed consent. The study was registered at www.clinicaltrials.gov (NCT02655731).
Laser balloon PVI
Antiarrhythmic drugs were discontinued prior to PVI before the time of five or more times half-life of the individual drug. Procedural details have been reported elsewhere. 12 Briefly, all procedures were performed under deep sedation, using boluses of midazolam and fentanyl No additional left atrial ablation was performed.
Left atrial voltage map and measurement of surface/intracardiac electrophysiological criteria
We obtained a left atrial voltage map in sinus rhythm before PVI. In case of AF at the start of the procedure, AF was externally defibrillated.
In line with previous reports, 7, 8 LALVA was defined as an area with ≥ 3 adjacent points with a peak-to-peak bipolar electrogram amplitude ≤0.5 mV during sinus rhythm. Surface and intracardiac electrocardiograms were recorded using a EP-system (Sensis, Siemens, Erlangen, Germany). Bipolar electrograms were filtered with a high-pass of 30 Hz and a low-pass of 300 Hz and amplified to 0.2-0.5 cm/V.
Continuous mapping settings for acquisition of points in the threedimensional mapping system module were as follows: cycle length range of sinus rhythm cycle ± 300 ms, local activation time stability Figure 1C ). All measurements of PWD, TTLAA, and rLALVA were independently performed by two blinded operators to account for interobserver variability. These parameters were also measured twice by the same operator for the intraobserver variability.
Postprocedural follow-up
Oral anticoagulation was resumed immediately after the procedure and continued for at least 8 weeks according to the individual stroke risk. A proton-pump inhibitor was administered for 2 weeks.
Antiarrhythmic drug therapy was discontinued after ablation. If atrial tachyarrhythmia recurred within 3 months after the index procedure, resumption of antiarrhythmic drugs and/or electrical cardioversion was performed. Patients attended outpatient visits at 3, 6, and 12 months including 72-hour Holter monitoring. In cases suggestive of atrial tachyarrhythmia recurrence, patients were equipped with an external event monitor. and PWD/TTLAA were calculated with Spearman's rank-correlation coefficient. We determined the cut-off value of PWD/TTLAA for the predictor indicating the presence of LALVA by receiver operating characteristic analysis. P < 0.05 was considered statistically significant.
Statistical analysis
All data were calculated using R (version 3.3.1, The R Foundation for Statistical Computing, Vienna, Austria).
RESULTS
Patient characteristics
A total of 100 patients were enrolled into the study. The baseline clinical characteristics are displayed in Table 1 . LALVA was identified in 23 patients during the index procedure ( Figure 2 ). The patients of group A were older and more often suffered from nonparoxysmal AF and diabetes (age, P < 0.001; paroxysmal AF and diabetes, P < 0.05).
Structural heart disease including nonischemic cardiomyopathies, hypertensive heart disease, postmyocarditis, and congenital heart diseases (ventricular septal defect and atrial septal defect) was observed in three of 23 (13%) patients of group A and in seven of 77 (9%) patients of group B (P = 0.693).
Procedural parameters and electrophysiological parameters at index procedure
In 99 of 100 (99%) patients, all pulmonary veins were successfully isolated (group A vs group B, P = 0.230) ( Table 2) . Focal irrigated TTLAA, r = 0.97, P < 0.001; rLALVA, r = 0.98, P < 0.001; intraobserver, PWD, r = 0.97, P < 0.001; TTLAA, r = 0.98, P < 0.001; rLALVA, r = 0.98, P < 0.001). LALVA was mainly found in left atrial anterior wall and septal wall in 22 (96%) and 13 (57%) patients of group A, respectively.
TA B L E 1 Baseline clinical characteristics
In group A, one patient experienced stroke ( Table 2 ). The patient visited the outpatient clinic 1 month after the ablation because of dysarthria. A magnetic resonance imaging showed mild cerebral infarction of thalamus. The patient was conservatively followed.
Another patient presented with delayed cardiac tamponade 24 hours Note: * Group A vs group B. Values are n (%), mean ± standard deviation, or median (interquartile range). LALVA = left atrial low-voltage area; PV = pulmonary vein; PVI = pulmonary vein isolation; PWD = total p-wave duration in lead II; rLALVA = relative extent of LALVA = extent of LALVA/left atrial surface area × 100 (%); RFC = radiofrequency current; TTLAA = time interval from the beginning of p-wave to the local activation in left atrial appendage.
TA B L E 2 Procedural and electrophysiological parameters at index procedure
after PVI. After pericardiocentesis the patient recovered without sequelae. In group B, phrenic nerve palsy occurred in two patients with full resolution before discharge. Another patient developed a false aneurysm that was treated by thrombin injection.
Follow-up
During 12 months' follow-up, 12 of 23 (52%) patients in group A and 67 of 77 (87%) patients in group B remained free of atrial tachyarrhythmia recurrence, respectively (P < 0.001; Figures 2 and 3A) . In patients with atrial tachyarrhythmia recurrence, two of 11 (18%) patients of group A and one of 10 (10%) patient of group B showed atrial tachycardia recurrence, respectively (P = 1.000). All the other patients with the recurrence presented with AF. In a post hoc subgroup analysis LALVA covering ≥ 10% of left atrial surface area was associated with an atrial tachyarrhythmia-free survival rate of 29% (four of 14 patients) (P < 0.001; Figure 3B) . A repeat procedure for atrial tachyarrhythmia recurrences was performed in 10/11 (91%) patients in group A and eight of 10 (80%) patients in group B. Permanent PVI was found in 31/39 (79%) pulmonary veins in group A and in 17/31 (55%) pulmonary veins in group B (P = 0.052).
Predictor for atrial tachyarrhythmia recurrence after laser balloon PVI
A Cox regression analysis was computed to identify predictors of atrial tachyarrhythmia recurrence. The univariate analysis showed significant differences in age, rLALVA, PWD, and TTLAA (Table 3 ). In the multivariate analysis, rLALVA was the only independent predictor of atrial tachyarrhythmia recurrence (hazard ratio: 1.051 per 1% increase in rLALVA; 95% confidence interval: 1.026-1.076, P < 0.001). PWD ). * P means the difference between all three groups. The difference between each two groups is as follows: group B versus patients with rLALVA < 10%, P = 0.505; group B versus patients with rLALVA ≥ 10%, P < 0.001; patients with rLALVA < 10% versus patients with rLALVA ≥ 10%, P = 0.037 [Color figure can be viewed at wileyonlinelibrary.com] Note: * Total p-wave duration in lead II (PWD) and time interval from the beginning of p-wave to the local activation in left atrial appendage (TTLAA) were excluded in multivariate analysis because of multicollinearity with relative extent of left atrial low-voltage area (LALVA) (= extent of LALVA/LA surface area × 100 [%]: rLALVA). AF = atrial fibrillation; CI = confidence interval; HR = hazard ratio.
TA B L E 3 Cox regression analysis for predictor for atrial tachyarrhythmia recurrence
and TTLAA showed multicollinearity with rLALVA as described below and were excluded from the multivariate analysis as explanatory variables.
Correlation between LALVA and PWD/TTLAA
PWD and TTLAA showed statistical correlation with rLALVA (PWD: r = 0.41, P < 0.01; TTLAA: r = 0.60, P < 0.001, Figure 4A and B). survival curve also revealed significant differences between patients with and without long PWD/TTLAA using these cut-off values (PWD, P = 0.032; TTLAA, P < 0.001) ( Figure 5 ).
DISCUSSION
The impact of LALVA on the outcome after balloon-based PVI has not been evaluated. This study determined the following major findings: (1) In patients with LALVA, atrial tachyarrhythmia recurrence rate after laser balloon PVI was significantly higher; (2) rLALVA was the only independent predictor for atrial tachyarrhythmia recurrence; and (3) PWD and TTLAA correlated with rLALVA and may help to stratify the risk of patients undergoing balloon ablation without a threedimensional mapping system. We confirmed the impact of LALVA on the atrial tachyarrhythmia recurrence after PVI using the ablation technology different from radiofrequency current (i.e., laser balloon).
Our study is considered useful for selection of a balloon technology and the prediction of the outcome after PVI when AF patients are predicted to have LALVA without a three-dimensional mapping system.
Previous studies indicated that PV-to-left atrium reconduction was a dominant factor for atrial tachyarrhythmia recurrences. 2, 14 However, a remapping study investigating laser balloon PVI demonstrated that some patients experience atrial tachyarrhythmia recurrences despite durable PVI suggesting proarrhythmic sources outside pulmonary veins. 15 Importantly, high PVI durability was observed in the whole repeat procedures in this study compared with the previous reports. 15, 16 Dukkipati et al. reported a 86% rate of persistent PVI at the remapping procedure in the whole population including patients with and without atrial tachyarrhythmia recurrences. 15 Reissmann et al. also
reported much lower rate of durable PVI (25/125 [20%] pulmonary veins) in the repeat procedures for atrial tachyarrhythmia recurrence after the initial laser balloon PVI. 16 The reason of the high durability of PVI in this study is thought to be due to PVI performed based on the high-dose energy concept. 13 In addition, the present study showed the risk of atrial tachyarrhythmia recurrence was elevated by 6%. 6 This resulted in a more than twofold increased relapse rate if left atrial scarring exceeded 10%. Our data are consistent with current literature in finding rLALVA as the only independent predictor for atrial tachyarrhythmia recurrences after laser balloon PVI. 6 We used rLALVA (i.e., extent of LALVA/left atrial surface area × 100 [%]), not the presence itself of rLALVA, as a variable in the analysis for the predictor of atrial tachyarrhythmia recurrence after laser balloon PVI to compare the previous reports analyzing the outcome after radiofrequency current PVI. 6, 9 On the other hand, since voltage mapping is not routinely used during balloon-guided PVI, simple electrophysiological variables were evaluated to identify patients with LALVA and hence worse outcomes.
PWD is an easily accessible surface electrocardiogram marker and showed only moderate sensitivity to detect LALVA but was associated with high negative predictive value. This may allow patients' selection prior to an invasive mapping. Moreover, TTLAA showed both high sensitivity and high negative predictive value for LALVA, which enables the operator to assign the appropriate strategy. The differences in sensitivity and the area under the curve of PWD/TTLAA in receiver operating characteristic analysis for the presence of LALVA may be explained by the fact that PWD represents the excitation time of the whole atrium, whereas TTLAA represents the conduction time from the sinus node to the initial left atrial appendage activation through the Bachmann bundle and left atrial anterior/posterior wall. Miyamoto et al. reported that LALVA was related to lower conduction velocity in left atrium. These findings seem to support this concept. 17 Park et al. also reported that p-wave amplitude in lead correlated with LALVA and that p-wave amplitude <0.1 mV in lead was an independent predictor of AF recurrence after irrigated radiofrequency of current PVI. 18 However, the area under the curve was only 0.705 and the study cohort was only patients with paroxysmal AF. In addition, cardiac magnetic resonance imaging or echocardiography might also be used to detect atrial tissue abnormalities. 5, 6, 19 Watanabe et al. showed a correlation between LALVA/left atrial total activation time/differences of time to peak strain of the local left atrial tissue using three-dimensional mapping system and three-dimensional speckle-tracking echocardiography. 19 However, the appeal of PWD and TTLAA lies in the ease of acquisition being readily available in routine clinical practice.
LIMITATIONS
First, the number of patients in this study was rather small but the results are consistent with previous reports on the incidence and distribution of LALVA. 20 Second, the study was not designed to develop an ablation strategy for patients with LALVA but existing data suggest that substrate modification (voltage abatement, box isolation, etc.) may be of value. 8 Third, the precision of voltage mapping depends on various factors such as electrode spacing, the conduction direction, or velocity in local left atrial tissue, the number of mapping points, and the cut-off values. A more exact high-resolution mapping might be necessary for ablation beyond PVI. 21 
CONCLUSION
Approximately one-quarter of patients have considerable LALVA in a nonselected AF population undergoing laser balloon PVI. The affected patients have a higher atrial tachyarrhythmia recurrence rate.
Easily accessible surface and/or intracardiac electrophysiological criteria (PWD/TTLAA) are helpful to identify LALVA patients thus allowing appropriate risk stratification to optimize the ablation strategy.
